Transdermal scopolamine: An alternative to ondansetron and droperidol for the prevention of postoperative and postdischarge emetic symptoms

Paul F. White, Jun Tang, Dajun Song, Jayne E. Coleman, Ronald H. Wender, Babatunde Ogunnaike, Alexander Sloninsky, Rajani Kapu, Mary Shah, Tom Webb

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

BACKGROUND: Given the controversy regarding the use of droperidol and the high cost of the 5-HT3 antagonists, a cost-effective alternative for routine use as a prophylactic antiemetic would be desirable. We designed two parallel, randomized, double-blind sham and placebo-controlled studies to compare the early and late antiemetic efficacy and adverse event profile of transdermal scopolamine (TDS) 1.5 mg, to ondansetron 4 mg IV, and droperidol 1.25 mg IV for antiemetic prophylaxis as part of a multimodal regimen in "at risk" surgical populations. METHODS: A total of 150 patients undergoing major laparoscopic (n = 80) or plastic (n = 70) surgery procedures received either an active TDS patch (containing scopolamine 1.5 mg) or a similar appearing sham patch 60 min before entering the operating room. All patients received a standardized general anesthetic technique. A second study medication was administered in a 2-mL numbered syringe containing either saline (for the two active TDS groups), droperidol, 1.25 mg, or ondansetron, 4 mg (for the sham patch groups), and was administered IV near the end of the procedure. The occurrence of postoperative nausea and vomiting/retching, need for rescue antiemetics, and the complete response rates (i.e., absence of protracted nausea or repeated episodes of emesis requiring antiemetic rescue medication) was reported. In addition, complaints of visual disturbances, dry mouth, drowsiness, and restlessness were noted up to 72 h after surgery. RESULTS: There were no significant differences in any of the emetic outcomes or need for rescue antiemetics among the TDS, droperidol, and ondansetron groups in the first 72 h after surgery. The complete response rates varied from 41% to 51%, and did not significantly differ among the treatment groups. The overall incidence of dry mouth was significantly more frequent in the TDS groups than in the droperidol and ondansetron groups (21% vs 3%). CONCLUSIONS: Premedication with TDS was as effective as droperidol (1.25 mg) or ondansetron (4 mg) in preventing nausea and vomiting in the early and late postoperative periods. However, the use of a TDS patch is more likely to produce a dry mouth.

Original languageEnglish (US)
Pages (from-to)92-96
Number of pages5
JournalAnesthesia and Analgesia
Volume104
Issue number1
DOIs
StatePublished - Jan 2007

Fingerprint

Emetics
Droperidol
Ondansetron
Scopolamine Hydrobromide
Antiemetics
Transdermal Patch
Mouth
Nausea
Vomiting
Serotonin 5-HT3 Receptor Antagonists
Costs and Cost Analysis
Postoperative Nausea and Vomiting
Psychomotor Agitation
General Anesthetics
Premedication
Sleep Stages
Syringes
Operating Rooms
Postoperative Period
Plastics

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Transdermal scopolamine : An alternative to ondansetron and droperidol for the prevention of postoperative and postdischarge emetic symptoms. / White, Paul F.; Tang, Jun; Song, Dajun; Coleman, Jayne E.; Wender, Ronald H.; Ogunnaike, Babatunde; Sloninsky, Alexander; Kapu, Rajani; Shah, Mary; Webb, Tom.

In: Anesthesia and Analgesia, Vol. 104, No. 1, 01.2007, p. 92-96.

Research output: Contribution to journalArticle

White, Paul F. ; Tang, Jun ; Song, Dajun ; Coleman, Jayne E. ; Wender, Ronald H. ; Ogunnaike, Babatunde ; Sloninsky, Alexander ; Kapu, Rajani ; Shah, Mary ; Webb, Tom. / Transdermal scopolamine : An alternative to ondansetron and droperidol for the prevention of postoperative and postdischarge emetic symptoms. In: Anesthesia and Analgesia. 2007 ; Vol. 104, No. 1. pp. 92-96.
@article{476965abe46c4eb083e719ecab805e20,
title = "Transdermal scopolamine: An alternative to ondansetron and droperidol for the prevention of postoperative and postdischarge emetic symptoms",
abstract = "BACKGROUND: Given the controversy regarding the use of droperidol and the high cost of the 5-HT3 antagonists, a cost-effective alternative for routine use as a prophylactic antiemetic would be desirable. We designed two parallel, randomized, double-blind sham and placebo-controlled studies to compare the early and late antiemetic efficacy and adverse event profile of transdermal scopolamine (TDS) 1.5 mg, to ondansetron 4 mg IV, and droperidol 1.25 mg IV for antiemetic prophylaxis as part of a multimodal regimen in {"}at risk{"} surgical populations. METHODS: A total of 150 patients undergoing major laparoscopic (n = 80) or plastic (n = 70) surgery procedures received either an active TDS patch (containing scopolamine 1.5 mg) or a similar appearing sham patch 60 min before entering the operating room. All patients received a standardized general anesthetic technique. A second study medication was administered in a 2-mL numbered syringe containing either saline (for the two active TDS groups), droperidol, 1.25 mg, or ondansetron, 4 mg (for the sham patch groups), and was administered IV near the end of the procedure. The occurrence of postoperative nausea and vomiting/retching, need for rescue antiemetics, and the complete response rates (i.e., absence of protracted nausea or repeated episodes of emesis requiring antiemetic rescue medication) was reported. In addition, complaints of visual disturbances, dry mouth, drowsiness, and restlessness were noted up to 72 h after surgery. RESULTS: There were no significant differences in any of the emetic outcomes or need for rescue antiemetics among the TDS, droperidol, and ondansetron groups in the first 72 h after surgery. The complete response rates varied from 41{\%} to 51{\%}, and did not significantly differ among the treatment groups. The overall incidence of dry mouth was significantly more frequent in the TDS groups than in the droperidol and ondansetron groups (21{\%} vs 3{\%}). CONCLUSIONS: Premedication with TDS was as effective as droperidol (1.25 mg) or ondansetron (4 mg) in preventing nausea and vomiting in the early and late postoperative periods. However, the use of a TDS patch is more likely to produce a dry mouth.",
author = "White, {Paul F.} and Jun Tang and Dajun Song and Coleman, {Jayne E.} and Wender, {Ronald H.} and Babatunde Ogunnaike and Alexander Sloninsky and Rajani Kapu and Mary Shah and Tom Webb",
year = "2007",
month = "1",
doi = "10.1213/01.ane.0000250364.91567.72",
language = "English (US)",
volume = "104",
pages = "92--96",
journal = "Anesthesia and Analgesia",
issn = "0003-2999",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Transdermal scopolamine

T2 - An alternative to ondansetron and droperidol for the prevention of postoperative and postdischarge emetic symptoms

AU - White, Paul F.

AU - Tang, Jun

AU - Song, Dajun

AU - Coleman, Jayne E.

AU - Wender, Ronald H.

AU - Ogunnaike, Babatunde

AU - Sloninsky, Alexander

AU - Kapu, Rajani

AU - Shah, Mary

AU - Webb, Tom

PY - 2007/1

Y1 - 2007/1

N2 - BACKGROUND: Given the controversy regarding the use of droperidol and the high cost of the 5-HT3 antagonists, a cost-effective alternative for routine use as a prophylactic antiemetic would be desirable. We designed two parallel, randomized, double-blind sham and placebo-controlled studies to compare the early and late antiemetic efficacy and adverse event profile of transdermal scopolamine (TDS) 1.5 mg, to ondansetron 4 mg IV, and droperidol 1.25 mg IV for antiemetic prophylaxis as part of a multimodal regimen in "at risk" surgical populations. METHODS: A total of 150 patients undergoing major laparoscopic (n = 80) or plastic (n = 70) surgery procedures received either an active TDS patch (containing scopolamine 1.5 mg) or a similar appearing sham patch 60 min before entering the operating room. All patients received a standardized general anesthetic technique. A second study medication was administered in a 2-mL numbered syringe containing either saline (for the two active TDS groups), droperidol, 1.25 mg, or ondansetron, 4 mg (for the sham patch groups), and was administered IV near the end of the procedure. The occurrence of postoperative nausea and vomiting/retching, need for rescue antiemetics, and the complete response rates (i.e., absence of protracted nausea or repeated episodes of emesis requiring antiemetic rescue medication) was reported. In addition, complaints of visual disturbances, dry mouth, drowsiness, and restlessness were noted up to 72 h after surgery. RESULTS: There were no significant differences in any of the emetic outcomes or need for rescue antiemetics among the TDS, droperidol, and ondansetron groups in the first 72 h after surgery. The complete response rates varied from 41% to 51%, and did not significantly differ among the treatment groups. The overall incidence of dry mouth was significantly more frequent in the TDS groups than in the droperidol and ondansetron groups (21% vs 3%). CONCLUSIONS: Premedication with TDS was as effective as droperidol (1.25 mg) or ondansetron (4 mg) in preventing nausea and vomiting in the early and late postoperative periods. However, the use of a TDS patch is more likely to produce a dry mouth.

AB - BACKGROUND: Given the controversy regarding the use of droperidol and the high cost of the 5-HT3 antagonists, a cost-effective alternative for routine use as a prophylactic antiemetic would be desirable. We designed two parallel, randomized, double-blind sham and placebo-controlled studies to compare the early and late antiemetic efficacy and adverse event profile of transdermal scopolamine (TDS) 1.5 mg, to ondansetron 4 mg IV, and droperidol 1.25 mg IV for antiemetic prophylaxis as part of a multimodal regimen in "at risk" surgical populations. METHODS: A total of 150 patients undergoing major laparoscopic (n = 80) or plastic (n = 70) surgery procedures received either an active TDS patch (containing scopolamine 1.5 mg) or a similar appearing sham patch 60 min before entering the operating room. All patients received a standardized general anesthetic technique. A second study medication was administered in a 2-mL numbered syringe containing either saline (for the two active TDS groups), droperidol, 1.25 mg, or ondansetron, 4 mg (for the sham patch groups), and was administered IV near the end of the procedure. The occurrence of postoperative nausea and vomiting/retching, need for rescue antiemetics, and the complete response rates (i.e., absence of protracted nausea or repeated episodes of emesis requiring antiemetic rescue medication) was reported. In addition, complaints of visual disturbances, dry mouth, drowsiness, and restlessness were noted up to 72 h after surgery. RESULTS: There were no significant differences in any of the emetic outcomes or need for rescue antiemetics among the TDS, droperidol, and ondansetron groups in the first 72 h after surgery. The complete response rates varied from 41% to 51%, and did not significantly differ among the treatment groups. The overall incidence of dry mouth was significantly more frequent in the TDS groups than in the droperidol and ondansetron groups (21% vs 3%). CONCLUSIONS: Premedication with TDS was as effective as droperidol (1.25 mg) or ondansetron (4 mg) in preventing nausea and vomiting in the early and late postoperative periods. However, the use of a TDS patch is more likely to produce a dry mouth.

UR - http://www.scopus.com/inward/record.url?scp=33847663698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847663698&partnerID=8YFLogxK

U2 - 10.1213/01.ane.0000250364.91567.72

DO - 10.1213/01.ane.0000250364.91567.72

M3 - Article

C2 - 17179250

AN - SCOPUS:33847663698

VL - 104

SP - 92

EP - 96

JO - Anesthesia and Analgesia

JF - Anesthesia and Analgesia

SN - 0003-2999

IS - 1

ER -